Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T22095
|
||||
| Former ID |
TTDC00214
|
||||
| Target Name |
Interleukin-17
|
||||
| Gene Name |
IL17A
|
||||
| Synonyms |
CTLA-8; Cytotoxic T lymphocyte-associated antigen 8; IL-17; IL-17A; IL17A
|
||||
| Target Type |
Successful
|
||||
| Disease | Arthritis [ICD9: 710-719; ICD10: M00-M25] | ||||
| Asthma [ICD10: J45] | |||||
| Plaque psoriasis [ICD10: L00-L99] | |||||
| Psoriatic arthritis [ICD9: 696; ICD10: L40.5, M07] | |||||
| Psoriasis [ICD9: 696; ICD10: L40] | |||||
| Rheumatoid arthritis [ICD9: 710-719, 714; ICD10: M05-M06] | |||||
| Severe plaque psoriasis [ICD10: L40] | |||||
| Function |
Induces stromal cells to produce proinflammatory and hematopoietic cytokines. Enhances the surface expression of ICAM1/intracellular adhesion molecule 1 in fibroblasts.
|
||||
| BioChemical Class |
Cytokine: interleukin
|
||||
| Target Validation |
T22095
|
||||
| UniProt ID | |||||
| Sequence |
MTPGKTSLVSLLLLLSLEAIVKAGITIPRNPGCPNSEDKNFPRTVMVNLNIHNRNTNTNP
KRSSDYYNRSTSPWNLHRNEDPERYPSVIWEAKCRHLGCINADGNVDYHMNSVPIQQEIL VLRREPPHCPNSFRLEKILVSVGCTCVTPIVHHVA |
||||
| Drugs and Mode of Action | |||||
| Drug(s) | Brodalumab | Drug Info | Approved | Severe plaque psoriasis | [1] |
| Ixekizumab | Drug Info | Approved | Plaque psoriasis | [2] | |
| Brodalumab | Drug Info | Phase 3 | Psoriasis | [3], [4] | |
| Ixekizumab | Drug Info | Phase 3 | Psoriatic arthritis | [5], [6] | |
| ABT-122 | Drug Info | Phase 2 | Rheumatoid arthritis | [7], [8] | |
| Brodalumab | Drug Info | Phase 2 | Asthma | [4], [9] | |
| CNTO-6785 | Drug Info | Phase 2 | Rheumatoid arthritis | [10] | |
| COVA322 | Drug Info | Phase 1/2a | Psoriasis | [11] | |
| ALX-0761 | Drug Info | Phase 1 | Psoriasis | [12] | |
| SCH-900117 | Drug Info | Phase 1 | Rheumatoid arthritis | [13] | |
| RG-4934 | Drug Info | Discontinued in Phase 1 | Arthritis | [14] | |
| Modulator | ABT-122 | Drug Info | |||
| ALX-0761 | Drug Info | [15] | |||
| Brodalumab | Drug Info | [16] | |||
| COVA322 | Drug Info | [15] | |||
| Ixekizumab | Drug Info | [17], [18] | |||
| SCH-900117 | Drug Info | [19] | |||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| Pathways | |||||
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| Inflammatory bowel disease (IBD) | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Interleukin signaling pathway | ||||
| Pathway Interaction Database | IL27-mediated signaling events | ||||
| IL23-mediated signaling events | |||||
| WikiPathways | TCR Signaling Pathway | ||||
| Allograft Rejection | |||||
| IL17 signaling pathway | |||||
| References | |||||
| REF 1 | Drugs@FDA (Edaravone) | ||||
| REF 2 | 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. doi: 10.1038/nrd.2017.14. | ||||
| REF 3 | ClinicalTrials.gov (NCT02029495) Study of Efficacy, Safety and Effect on Radiographic Progession of Brodalumab in Subjects With Psoriatic Arthritis. U.S. National Institutes of Health. | ||||
| REF 4 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7540). | ||||
| REF 5 | ClinicalTrials.gov (NCT01474512) A Phase 3 Study in Participants With Moderate to Severe Psoriasis. U.S. National Institutes of Health. | ||||
| REF 6 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7541). | ||||
| REF 7 | ClinicalTrials.gov (NCT02349451) A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate. U.S. National Institutes of Health. | ||||
| REF 8 | ClinicalTrials.gov (NCT02433340) Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study | ||||
| REF 9 | Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis | ||||
| REF 10 | ClinicalTrials.gov (NCT01909427) An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy. U.S. National Institutes of Health. | ||||
| REF 11 | ClinicalTrials.gov (NCT02243787) Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis | ||||
| REF 12 | ClinicalTrials.gov (NCT02156466) Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects | ||||
| REF 13 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029914) | ||||
| REF 14 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032677) | ||||
| REF 15 | Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. doi: 10.1038/nrd4478. | ||||
| REF 16 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
| REF 17 | Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5. | ||||
| REF 18 | A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response totumor necrosis factor inhibitors. Arthritis Rheumatol. 2014 Jul;66(7):1693-704. | ||||
| REF 19 | Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012 Oct;11(10):763-76. doi: 10.1038/nrd3794. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.